Prevalence and prognostic value of monoclonal gammopathy in heart failure patients with preserved ejection fraction: A prospective study

Ana Devesa1, Celia Rodríguez Olleros2, Xhorxhi Kaçi1,3, Elham Askari4, Andrea Camblor Blasco1, Ana María Pello Lázaro1, Sandra Gómez Talavera1,3,6, Juan Gómez Octavio2, Gregoria Lapeña7, Felipe Navarro1,6, José Tuñón1,6, Borja Ibáñez1,5,6, Álvaro Aceña1

1Department of Cardiology, IIS-Hospital Universitario Fundación Jiménez Díaz — Quironsalud, Madrid, Spain
2Department of Internal Medicine, Hospital Universitario Fundación Jiménez Díaz — Quironsalud, Madrid, Spain
3School of Medicine and Surgery, University of Milan, Italy
4Department of Hematology, Hospital Universitario Fundación Jiménez Díaz — Quironsalud, Madrid, Spain
5Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
6Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
7Department of Nuclear Medicine, Hospital Universitario Fundación Jiménez Díaz — Quironsalud, Madrid, Spain

Abstract

Background: Heart failure (HF) with preserved ejection fraction (HFpEF) and monoclonal gammopathy of uncertain significance (MGUS) are two entities that share pathophysiological mechanisms. The aim herein, was to assess the prevalence of MGUS in patients with HFpEF and no left ventricular (LV) hypertrophy, as well as its association with a pre-specified clinical endpoint at 12 months.

Methods: The present study prospectively enrolled 69 patients admitted with HF, with ejection fraction ≥ 50%, and LV wall thickness < 12 mm. All patients were screened for MGUS. Clinical events were determined over a 12 month follow-up. The pre-specified composite clinical endpoint was readmission for HF or death.

Results: The prevalence of MGUS in this population was 13%. There were no differences in the incidence of the composite clinical endpoint between patients with and without MGUS. Multivariate analysis showed that treatment with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) was associated with fewer clinical events (HR: 0.153, 95% CI: 0.037–0.622, p = 0.009) and indicated a trend to lower risk of readmission for HF and death. Beta-blockers were associated with lower rates of the composite clinical endpoint (HR: 0.192, 95% CI: 0.05–0.736, p = 0.016), readmission for HF (HR: 0.272, 95% CI: 0.087–0.851, p = 0.025) and indicated a trend to lower mortality. Moreover, potassium serum levels > 5 mEq/L were associated with higher rates of the composite endpoint (HR: 6.074, 95% CI: 1.6–22.65, p = 0.007).

Conclusions: The prevalence of MGUS in patients with HFpEF without hypertrophy was 3-fold that of the general population. There was no significant correlation between clinical outcomes and the presence of MGUS. Beta-blockers and ACEIs/ARBs reduced the composite of mortality and readmissions for HF in HFpEF patients. Hyperpotassemia was related to worse prognosis. (Cardiol J 2022; 29, 2: 216–227)

Key words: monoclonal gammopathy, heart failure, inflammation, ACEI,ARB
Introduction

Heart failure (HF) is a clinical syndrome characterized by symptoms and signs. HF is caused by structural and/or functional cardiac abnormalities, resulting in reduced cardiac output and/or elevated intracardiac pressure at rest or during stress [1]. According to European guidelines [1] patients present HF with preserved ejection fraction (HFpEF) when left ventricular ejection fraction (LVEF) is ≥ 50%, with elevated levels of natriuretic peptides (B-type natriuretic peptide [BNP] > 100 pg/mL and/or N-terminal pro-BNP [NT-proBNP] > 300 pg/mL in the acute setting) and at least one additional criterion, such as relevant structural heart disease (left ventricular hypertrophy [LVH] and/or left atrial enlargement) or diastolic dysfunction. Recent diagnostic algorithms suggest some functional, morphological and biomarker-related criteria for a more accurate diagnosis of HFpEF [2].

Heart failure affects ≥ 10% of ≥ 70-year old population and up to 50% of all cases of HF are believed to be caused by HFpEF [1, 3–5]. Its prevalence has been increasing in recent decades, related to the higher percentage of elderly individuals in the population. However, epidemiological data are difficult to acquire. One meta-analysis found a mortality rate of 12.1% during the first year [6]. A new pathophysiological model for HFpEF has been recently suggested [5], explaining it as an inflammatory disease. Typically, HFpEF patients are elderly with several inflammation-related comorbidities (i.e., diabetes, hypertension), which may explain the link between those proinflammatory entities and the presence of HFpEF.

Monoclonal gammopathies (MGs) are a group of entities associated with the proliferation of a single clone of plasma cells. MGs include conditions ranging from monoclonal gammopathy of uncertain significance (MGUS), multiple myeloma (MM), lymphoplasmacytic lymphoma (LL), and primary amyloidosis (AL) [7, 8]. Patients with MGUS present monoclonal immunoglobulin concentrations of ≤ 3 g/dL in serum; in the absence of lytic bone lesions, anemia, hypercalcemia, and kidney failure related to the proliferation of monoclonal plasma cells; and ≤ 10% of plasma cells in the bone marrow [7, 8]. The prevalence of MGUS is 4.22% among individuals ≥ 60 years of age in the general population [8]. Clinical relevance of MGs lies in their high prevalence and underdiagnosis, but mainly due to the risk of progression to other entities (16% at 10 years) [8]. All the diseases within the MG spectrum may show cardiac involvement, with myocardial deposits of paraprotein or its components, that generate a diastolic alteration leading to a restrictive pattern and HF [9–13]. MGs trigger a proinflammatory state [14] that could contribute to the development of diastolic alterations at a cardiac level.

Both HFpEF and MGUS are increasing in prevalence among the older population. Given the pathogenesis, both may rely on immune system activation and inflammation mechanisms [14, 15], suggesting a possible link between them.

HFpEF has been described in patients without LV hypertrophic remodeling [16] who accomplished other of the definition criteria for HFpEF [1, 2]. Patients with LVH have a high incidence of infiltrative diseases [17]. In this study it was sought to select patients without significant hypertrophy (< 12 mm), thereby with less probability to present with an infiltrative disease and try to establish a correlation between them and the presence of MGUS.

This study sought to determine whether a correlation exists between HFpEF without significant LVH and the presence of MGUS. Based on the epidemiological resemblances and a possible inflammatory process underlying both entities, it was hypothesized that MGUS could be more prevalent in cases of HFpEF than in the general population. Testing the secondary hypothesis, was an inquiry as to whether a correlation exists between the prevalence of MGUS and the clinical outcomes in HFpEF (composite endpoint of rehospitalization for HF and mortality, and each component of the combined endpoint).

Methods

Study design

This is an observational, prospective, single-center, and prevalence study. Only those patients who provided signed written consent were enrolled. The study was approved by Fundación Jiménez Díaz Ethics Committee.

Study population

Patients were recruited following admission to the Fundación Jiménez Díaz hospital in Madrid. All patients had a diagnosis of HFpEF (see inclusion criteria) at the time of hospitalization. The hospital database updated with patient status, test results, scans, and assessments from all hospital departments. Furthermore, the online health-care database for the entire region of Madrid was searched to determine whether patients had presented to an
Emergency Department or other service and the exact date of death in cases where the patient died.

**Inclusion criteria**
- Inclusion criteria included:
  - age ≥ 18 years;
  - clinical signs and/or symptoms typical of HF (such as rales and crackles at auscultation, pulmonary congestion as seen through chest X-rays, third heart sound), BNP > 100 pg/mL or NT-proBNP > 300 pg/mL at hospitalization, in full accordance with current guidelines [1];
  - LVEF ≥ 50% at hospitalization (evidenced in a recent echocardiogram at point of care or in loco);
  - LV wall thickness < 12 mm at thickest point (recent echocardiogram at point of care or in loco).

**Exclusion criteria**
- All patients that met any of the criteria below were excluded from the study:
  - pre-existing heart condition that may explain HF (i.e. moderate to severe valvular disease, prosthetic valve, severe anemia or hyperdynamic circulation, advanced second- or third-degree atrioventricular block proven by a pathologic electrocardiogram track, etc.);
  - substantial or severe comorbidity that, according to the enroller’s judgement, would indicate deteriorated cardiac function;
  - previous or known diagnosis of multiple myeloma, amyloidosis, or lymphoplasmacytic lymphoma;
  - autoinflammatory disease or infection that could explain MG.

**Enrollment, physical examination, laboratory tests, and imaging**
- Patients who met all inclusion and none of the exclusion criteria provided a written statement of consent, in accordance with the requirements of the local ethics committee and in adherence of Spanish law.
  - Upon enrollment, all patients underwent a whole-body physical examination and the following laboratory tests were performed: complete blood count, basic biochemical markers, serum proteins, protein electrophoresis test, immuno fixation electrophoresis (serum and urine) and light chains (serum and urine). As mentioned in inclusion criteria, one of the criteria for the diagnosis of HF was BNP > 100 pg/mL or NT-proBNP > 300 pg/mL at hospitalization [1]. Moreover, another variable was created, “Elevated natriuretic peptides”, that was defined as levels of BNP or NT-proBNP greater than or equal to the median (BNP > 368 pg/mL or NT-proBNP > 1900 pg/mL). Demographic data, cardiovascular risk factors, clinical history, echocardiographic parameters and treatments were recorded. Enlarged left atrium (LA) was considered when LA maximum diameter in a parasternal long-axis view was ≥ 35 mm or when LA major length in an apical four-chamber view was ≥ 53 mm [18]. Diastolic function was classified as normal diastolic function, indeterminate or diastolic dysfunction [19].
  - When a monoclonal component was found, patients were referred to the Hematology Department, where they underwent a complete evaluation and risk stratification. MGUS was defined as present monoclonal immunoglobulin concentrations of ≤ 3 g/dL in serum, in the absence of lytic bone lesions, anemia, hypercalcemia, and kidney failure related to the proliferation of monoclonal plasma cells; and ≤ 10% of plasma cells in the bone marrow [7, 8].
  - At 12 months, the electronic medical records were reviewed for events (hospitalization for HF and mortality).

**Data management and processing**
- Two data sheets were used for data collection and analysis:
  - Database #1: Excel spread sheet containing the pairings (Last name, Name, Medical record number), and the study number (randomized number, not related to the patient in any way or by its clinical file number, and not generated from the patient’s data). This database was the only one containing the patients’ personal data, and it contained no data related to the study or any data related to their health;
  - Database #2: The study number was paired to all of the data retrieved and gathered from the patient. This database contained sensible information but when consulted alone, patient identification was impossible.
  - Once the enrollment process was complete, only the second database was used for the purpose of analysis, making the process fully anonymous and non-traceable.
  - All data were handled and processed in full accordance with local and European law.

**Statistical analysis**
- Quantitative variables are displayed as medians (interquartile range). Qualitative variables appear as percentages.
To predict the endpoint at 12 months, a univariate Cox regression analysis for all variables was performed. Next, a multivariate analysis was carried out to determine whether any of the variables could independently predict major events with the variables with a p value in univariate analysis < 0.2.

The Kaplan-Meier curves and log-rank test were used to compare time to outcome according to those variables significantly associated with a higher risk of developing the primary outcome.

Analyses were performed with SPSS 19.0 (SPSS Inc., New York). Statistical tests in which p < 0.05 (two-tailed) were considered significant.

Results

Study population

Two hundred nine patients admitted with HF to the Fundación Jiménez Díaz were preselected between July 17, 2017 and November 11, 2018. One hundred thirty-eight patients were excluded (Fig. 1). Two patients were excluded of the analyses because they didn’t undergo blood tests. The final number of patients analyzed was 69.

Statement of ethics

Only patients that signed written consent for the study were enrolled. The study was approved by Fundación Jiménez Díaz Ethical Committee.

Baseline characteristics

The mean age was 83 years, with 46.4% males (Table 1). Atrial fibrillation was present in 63.8%. Other cardiovascular risk factors that can indicate underlying inflammatory mechanisms were very frequently present, such as diabetes (30.4%), dyslipidemia (56.5%) and hypertension (81.2%). Most patients were under loop diuretics (73.9%) and 50.7% were receiving angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Median BNP was 368 pg/mL and median NT-proBNP was 1900 pg/mL. Natriuretic peptides were elevated over the median (BNP > 368 pg/mL, NT-proBNP > 1900 pg/mL) in 59.6% of patients. Potassium levels were higher than 5 mEq/L at admission in 10.1% of the patients. Characteristics by groups (combined endpoint, re-hospitalization for HF and mortality) are presented in Tables 1 and 2.
**Table 1.** Basal characteristics (total population and combined endpoint of mortality and readmission for heart failure).

| Population description | Total (n = 69) | No combined endpoint (n = 35) | Combined endpoint (n = 34) | P  |
|------------------------|----------------|-----------------------------|--------------------------|----|
| Age [years]            | 83 (77–86)     | 82 (77–87)                  | 83 (79–86)               | 0.605|
| Males                  | 46.4           | 51.1                        | 37.5                     | 0.282|
| Diabetic               | 30.4           | 31.1                        | 29.2                     | 0.867|
| Smokers                | 32.4           | 31.8                        | 33.3                     | 0.898|
| Dyslipidemia           | 56.5           | 60                          | 50                       | 0.426|
| Arterial hypertension  | 81.2           | 84.4                        | 75                       | 0.343|
| Atrial fibrillation    | 63.8           | 62.2                        | 66.7                     | 0.715|
| Ischemic heart disease | 14.5           | 15.6                        | 12.5                     | 0.732|
| MGUS                   | 13             | 15.6                        | 8.3                      | 0.403|

**Medication at day 1**

| Description            | Total (n = 69) | No combined endpoint (n = 35) | Combined endpoint (n = 34) | P  |
|------------------------|----------------|-----------------------------|--------------------------|----|
| ASA                    | 24.6           | 24.4                        | 25                       | 0.959|
| Anticoagulation        | 63.8           | 64.4                        | 62.5                     | 0.873|
| Clopidogrel            | 4.4            | 2.2                         | 8.3                      | 0.276|
| ACEIs or ARBs         | 50.7           | 60                          | 33.3                     | 0.038|
| Beta-blockers          | 43.5           | 53.3                        | 25                       | 0.027|
| CCB                    | 17.4           | 15.6                        | 20.8                     | 0.583|
| Thiazide diuretics     | 18.8           | 13.3                        | 29.2                     | 0.117|
| Loop diuretics         | 73.9           | 75.6                        | 70.8                     | 0.427|
| MRA                    | 14.5           | 8.9                         | 25                       | 0.081|
| Digoxin                | 8.7            | 6.7                         | 4.7                      | 0.420|
| Statins                | 52.2           | 57.8                        | 41.7                     | 0.204|
| Antiarrhythmics        | 7.2            | 6.7                         | 8.3                      | 0.8 |

**Laboratory values**

| Description          | Total (n = 69) | No combined endpoint (n = 35) | Combined endpoint (n = 34) | P  |
|----------------------|----------------|-----------------------------|--------------------------|----|
| Albumin levels [g/dL]| 4.00 (3.75–4)  | 4.00 (3.5–4)                | 4.00 (4–4)               | 1  |
| Total protein count  | 6.5 (6–7.07)   | 6.7 (6.1–7.125)             | 6.3 (5.7–7.07)           | 0.370|
| Creatinine [mg/dL]   | 1.1 (0.8–1.377)| 1.1 (0.8–1.33)              | 1.08 (0.8–1.57)          | 0.446|
| eGFR [ml/min]        | 56.9 (46.4–74)| 57 (48–77.9)                | 56.4 (37.5–68.1)         | 0.205|
| Glycerina [mg/dL]    | 104 (88.5–27)  | 105 (92–123)                | 101 (86.5–141)           | 0.855|
| Hemoglobin [g/dL]    | 12.2 (11.1–13.15)| 12.2 (11.3–13)               | 11.9 (10.9–13.5)         | 0.806|
| Platelet count [n/mm³]| 208000        | 215000                      | 192000                   | 0.453|
| WBC count [n/mm³]    | 6930 (5770–8975)| 7000 (6000–9150)             | 6425 (5700–8395)         | 0.326|
| Sodium [mEq/L]       | 139 (136–141)  | 139 (136–142)               | 139 (135–141)            | 0.519|
| Potassium [mEq/L]    | 4.2 (3.8–4.55) | 4.2 (3.7–4.3)               | 4.2 (4–4.7)              | 0.225|
| NT-proBNP [pg/mL]    | 1900 (1096–2960)| 1600 (894–2628)             | 3140 (2200–9990)         | 0.121|
| BNP [pg/mL]          | 368 (130–885)  | 218 (112–495)               | 595 (400.5–1128)         | 0.003|
| Potassium > 5 mEq/L  | 10.1           | 4.4                         | 20.8                     | 0.049|
| Natriuretic peptides over the median† | 59.6 | 51.2 | 81.3 | 0.047|

**Echocardiographic values**

| Description | Total (n = 69) | No combined endpoint (n = 35) | Combined endpoint (n = 34) | P  |
|-------------|----------------|-----------------------------|--------------------------|----|
| Ejection fraction | 60 (55–60) | 60 (55–60) | 60 (51–63.7) | 0.742|
| LA (PLA) [mm]   | 41 (36–45)    | 41 (37–45)                  | 41 (36–45)               | 0.354|
| LA (AFC) [mm]   | 59 (53–63.5)  | 59 (55–63)                  | 58 (50–65)               | 0.414|
| LA dilatation   | 88.4          | 86.7                        | 91.7                     | 0.54 |
| Diastolic dysfunction or non-evaluable | 98.6 | 97.3 | 100 | 0.282|

Values are median (interquartile range) or percentages. †Natriuretic peptides over the median were defined as NT-proBNP levels > 1900 pg/mL or BNP > 368 pg/mL. ACEIs — angiotensin converter enzyme inhibitors; AFC — apical four chamber; ARBs — angiotensin II receptor blockers; ASA — acetylsalicylic acid; BNP — B-type natriuretic peptide; CCB — calcium channel blockers; eGFR — estimated glomerular filtration rate; LA — left atrium; MGUS — monoclonal gammopathy uncertain significance; MRA — mineral corticoid receptor antagonists; NT-proBNP — N-terminal pro-BNP; PLA — parasternal long axis; WBC — white blood cell.
### Table 2. Basal characteristics (readmission for heart failure [HF] and mortality).

| Population description | Readmission for HF (n = 18) | No readmission for HF (n = 51) | P  | Mortality (n = 11) | No mortality (n = 58) | P  |
|-----------------------|----------------------------|--------------------------------|----|-------------------|----------------------|----|
| Age [years]           | 83.5 (81.8–87.2)          | 81 (77–86)                    | 0.108 | 82 (77–86) | 83 (77–87) | 0.693 |
| Males                 | 33.3                      | 51                             | 0.201 | 36.4             | 48.3              | 0.470 |
| Diabetic              | 27.8                      | 31.4                           | 0.776 | 18.2             | 32.8              | 0.344 |
| Smokers               | 27.8                      | 33.3                           | 0.629 | 36.4             | 31                | 0.756 |
| Dyslipidemia          | 44.4                      | 60.8                           | 0.233 | 54.5             | 56.9              | 0.885 |
| Arterial hypertension | 77.8                      | 82.4                           | 0.670 | 63.6             | 84.5              | 0.117 |
| Atrial fibrillation   | 72.2                      | 60.8                           | 0.388 | 54.5             | 65.5              | 0.49  |
| Ischemic heart disease| 5.6                       | 17.6                           | 0.237 | 18.2             | 13.8              | 0.706 |
| MGUS                  | 5.6                       | 15.7                           | 0.295 | 9.1              | 13.8              | 0.674 |
| **Medication at day 1** |                          |                                |      |                   |                     |    |
| ASA                   | 16.7                      | 27.5                           | 0.366 | 27.3             | 24.1              | 0.825 |
| Anticoagulation       | 72.2                      | 60.8                           | 0.388 | 54.5             | 65.5              | 0.490 |
| Clopidogrel           | 11.1                      | 2                              | 0.15  | 9.1              | 3.4               | 0.426 |
| ACEIs or ARBs         | 38.9                      | 54.9                           | 0.246 | 55.2             | 52.8              | 0.102 |
| Beta-blockers         | 22.2                      | 51                             | 0.041 | 18.2             | 48.3              | 0.082 |
| CCB                   | 22.2                      | 15.7                           | 0.531 | 9.1              | 19                | 0.440 |
| Thiazide diuretics    | 22.2                      | 17.6                           | 0.670 | 36.4             | 15.5              | 0.117 |
| Loop diuretics        | 66.7                      | 76.5                           | 0.275 | 81.8             | 72.4              | 0.691 |
| MRA                   | 22.2                      | 11.8                           | 0.286 | 27.3             | 12.1              | 0.202 |
| Digoxin               | 16.7                      | 5.9                            | 0.18  | 0                | 10.3              | 0.999 |
| Statins               | 38.9                      | 56.9                           | 0.194 | 45.5             | 53.4              | 0.627 |
| Antiarrhythmics       | 11.1                      | 5.9                            | 0.469 | 0                | 8.6               | 0.999 |
| **Laboratory values** |                          |                                |      |                   |                     |    |
| Albumin levels [g/dL] | 4 (4–4)                   | 4.00 (3.5–4)                  | 1    | 4 (4–4)          | 4 (3.75–4)       | 1    |
| Total protein count [g/dL] | 6.3 (5.6–7)          | 6.7 (6.1–7.2)                 | 0.220 | 6.4 (5.7–7.7)   | 6.5 (6.05–6.9)   | 0.908 |
| Creatinine [mg/dL]    | 1.05 (0.8–1.32)          | 1.1 (0.8–1.37)                | 0.967 | 1.19 (0.8–1.7)  | 1.07 (0.8–1.3)   | 0.321 |
| eGFR [mL/min]         | 56.9 (47–68.1)           | 56.9 (45–76)                  | 0.481 | 51 (37–68.1)    | 57 (48–74.5)     | 0.235 |
| Glycemia [mg/dL]      | 95                        | 107                            | 0.280 | 97              | 104.5           | 0.354 |
| Hemoglobin [g/dL]     | 11.8 (10.9–3.6)          | 12.2 (11.2–13.1)              | 0.722 | 11. (10.9–14)  | 12.2 (11.2–13.1) | 0.426 |
| Platelet count [n/mm$^3$] | 192000                   | 215000                        | 0.328 | 185000          | 213500          | 0.566 |
| WBC count [n/mm$^3$]  | 6425                      | 7000                           | 0.176 | 5900           | 7000            | 0.363 |
| Segmented neutrophils [%] | 67.9 (60.5–84.3)      | 67 (62–73)                    | 0.448 | 67.1 (61.3–73) | 67.9 (61.8–75.5) | 0.87  |
| Sodium [mEq/L]        | 139.5 (136–141)          | 139 (136–141)                 | 0.896 | 137 (135–140)  | 136 (139–141)   | 0.361 |
| Potassium [mEq/L]     | 4.3 (3.9–4.9)            | 4.2 (3.7–4.3)                 | 0.166 | 4.2 (4–4.6)    | 4.1 (3.7–4.5)   | 0.616 |
| NT-proBNP [pg/mL]     | 2350                      | 1900                           | 0.748 | 6915 (1681.5–22897.5) | 1900 | 0.113 |
| BNP [pg/mL]           | 595                       | 262                            | 0.147 | 522.5          | 281.5           | 0.197 |
| Potassium > 5 mEq/L   | 22.2                      | 5.9                            | 0.064 | 9.1            | 10.3           | 0.9   |
| Natriuretic peptides over the median† | 75                        | 55.6                           | 0.231 | 71.4           | 58             | 0.5   |
| **Echocardiographic values** |                          |                                |      |                   |                     |    |
| Ejection fraction     | 60 (58.5–60)             | 60 (55–60)                    | 0.305 | 60 (50–65)     | 60 (55–60)     | 0.993 |
| LA (PLA) [mm]         | 41.5 (36–46.7)           | 41 (36.2–44.7)                | 0.64  | 38 (33–42.5)   | 42 (37–45.5)   | 0.207 |
| LA (AFC) [mm]         | 59 (50.7–69.5)           | 59 (54–62)                    | 0.633 | 57 (50–60)    | 60 (54.7–65)   | 0.083 |
| LA dilatation         | 94.4                      | 86.3                           | 0.369 | 81.8           | 89.7           | 0.463 |
| Diastolic dysfunction or non-evaluable | 100                      | 98                             | 0.355 | 100            | 98.3          | 0.205 |

Values are median (interquartile range) or percentages. †Natriuretic peptides over the median were defined as NT-proBNP levels > 1900 pg/mL or BNP > 388 pg/mL. ACEIs — angiotensin converter enzyme inhibitors; AFC — apical four chamber; ARBs — angiotensin II receptor blockers; ASA — acetylsalicylic acid; BNP — B-type natriuretic peptide; CCB — calcium channel blockers; eGFR — estimated glomerular filtration rate; LA — left atrium; MGUS — monoclonal gammapathy uncertain significance; MRA — mineral corticoid receptor antagonists; NT-proBNP — N-terminal pro-BNP; PLA — parasternal long axis; WBC — white blood cell
Prevalence of MGUS in the HFpEF patient cohort

The prevalence of MGUS among the patients with HFpEF and LV wall thickness < 12 mm, was 13% (n = 9) (Table 1). There were no significant differences in the number of patients with or without MGUS by group (Tables 1 and 2).

Eight patients had a low risk MGUS and did not need any other complementary test; a follow-up was programmed by the Hematology Department in these patients. One patient did not enter into the study because of death.

Clinical events (combined endpoint, hospitalization for HF, mortality)

At 12-month follow-up, 34 (49.2%) patients had met the composite endpoint of mortality or rehospitalization for HF. 18 (26%) patients had been readmitted for HF at least once and 11 (16%) patients had died (Tables 1 and 2). In the group with diagnosis of MGUS, 2 (22%) of patients met the composite clinical endpoint, 1 (11.1%) patient was readmitted for HF and 1 (11.1%) patient died; versus 22 (37.5%), 17 (28.3%) and 10 (16.7%), respectively in the group without MGUS (Table 3).

Factors influencing the outcome

The single variable Cox regression was performed for each category of data with regard to the composite endpoint, readmission for HF and mortality. A multivariate Cox analysis showed that patients taking ACEIs/ARBs were less likely to present the combined clinical endpoint (hazard ratio [HR]: 0.153, 95% confidence interval [CI]: 0.037–0.622, p = 0.009), and had a trend to lower risk of readmission for HF (HR: 0.353, 95% CI: 0.121–1.026, p = 0.056) and mortality (HR: 0.275, 95% CI: 0.073–1.041, p = 0.057; Tables 4–6). Moreover, patients taking beta-blockers were also less likely to present the combined clinical endpoint (HR: 0.192, 95% CI 0.05–0.736, p = 0.016), to be readmitted for HF (HR: 0.272, 95% CI: 0.087–0.851, p = 0.025) and had a trend to lower risk of death (HR: 0.27, 95% CI: 0.058–1.249, p = 0.094; Tables 4–6). Besides, patients with potassium serum levels > 5 mEq/L at admission were more likely to present the combined clinical endpoint (HR: 6.074, 95% CI: 1.6–22.65, p = 0.007; Table 3). Patients taking clopidogrel had higher risk of being readmitted for HF (HR: 7.938, 95% CI: 1.458–43.227, p = 0.017; Table 5).

### Table 3. Outcomes by group (presence or absence monoclonal gammopathy of uncertain significance [MGUS])

|                  | MGUS (n = 9) | No MGUS (n = 60) | P   |
|------------------|-------------|-----------------|-----|
| Composite endpoint | 2 (22.2%)   | 22 (36.7%)      | 0.403 |
| Admission for HF  | 1 (11.1%)   | 17 (28.3%)      | 0.295 |
| Mortality         | 1 (11.1%)   | 10 (16.7%)      | 0.674 |

Values are number of patients and percentages. HF — heart failure

### Table 4. Multivariate Cox regression for combined endpoint (admission for heart failure and mortality)

| Variable          | Hazard ratio | 95% confidence interval | P (multivariate) |
|-------------------|--------------|-------------------------|------------------|
| ACEIs or ARBs     | 0.153        | 0.037–0.622             | 0.009            |
| Beta-blockers     | 0.192        | 0.05–0.736              | 0.016            |
| Potassium > 5 mEq/L | 6.074        | 1.6–22.65               | 0.007            |

ACEIs — angiotensin converter enzyme inhibitors; ARBs — angiotensin II receptor blockers

### Table 5. Multivariate Cox regression for admission for heart failure.

| Variable         | Hazard ratio | 95% confidence interval | P (multivariate) |
|------------------|--------------|-------------------------|------------------|
| ACEIs or ARBs    | 0.353        | 0.121–1.026             | 0.056            |
| Beta-blockers    | 0.272        | 0.087–0.851             | 0.025            |
| Clopidogrel      | 7.938        | 1.458–43.227            | 0.017            |

ACEIs — angiotensin converter enzyme inhibitors; ARBs — angiotensin II receptor blockers
The Kaplan-Meier curves showed that taking beta-blockers resulted in lower rates of the combined clinical endpoint and readmission for HF, with a trend to lower mortality (Fig. 2A–C). ARBs/ACEIs were protective in terms of the combined clinical endpoint and had a trend to decreased...

**Figure 2.** Kaplan-Meier curves comparing patients taking beta-blockers (BB) with patients not taking beta-blockers; A. Time to composite endpoint; B. Time to rehospitalization for heart failure; C. Time to death.

**Table 6.** Uni- and multivariate Cox regression for admission for mortality.

| Variable     | Hazard ratio | 95% confidence interval | P (multivariate) |
|--------------|--------------|-------------------------|------------------|
| ACEls or ARBs| 0.275        | 0.073–1.041             | 0.057            |
| Beta-blockers| 0.27         | 0.058–1.249             | 0.094            |

ACEls — angiotensin converter enzyme inhibitors; ARBs — angiotensin II receptor blockers
rehospitalization for HF (Fig. 3A, B). Moreover, patients with potassium serum levels > 5 mEq/L at admission were more likely to present the combined endpoint when compared to those with lower potassium levels (Fig. 4).

**Discussion**

The prevalence of MGUS in patients with HFpEF and LV wall thickness < 12 mm was 3 times higher than that in the general population (13% vs. 4.22%). It can therefore be deduced that patients with MGUS should be assessed for HF symptoms. In future, MGUS may be incorporated into a diagnostic work-up that may include cardiac damage markers, or echocardiography [20, 21].

For the clinical endpoints, rates of readmission for HF at 12 months was 26%, which is lower than previously described, which might be related to the fact that previous studies usually include both patients with reduced and preserved ejection fraction [22]. The mortality rate of these patients was 16% at 1 year, which was slightly higher than in previous studies [22].

A correlation between outcomes and presence or absence of MGUS could not be demonstrated. Since there is no direct proof of cardiotoxicity in MGUS, MGUS may be an initial phase (as a first laboratory sign) of protein deposit disease, such as amyloidosis, or even progress into multiple myeloma. Even though amyloidosis would drastically change the outcome of any patients in the sample...
presenting the disease, patients were specifically selected that had an LV wall thickness < 12 mm, possibly excluding most of the amyloid patients, which usually present with LVH. Moreover, the follow-up period in this study was far too short for these entities to manifest and consequently alter the outcome of MGUS patients.

ACEIs/ARBs were related to better outcomes in terms of the combined endpoint and had a trend to lower rates of readmission for HF and mortality at 12 months. Though patients were not categorized by the New York Heart Association/American Heart Association functional class, it was deduced from these results that HFpEF patients might benefit from ACEIs/ARBs as this therapy approach would downgrade their risk stratum. These results are encouraging, especially considering that the most promising drug, sacubitril/valsartan showed no benefit when compared to valsartan in the PARAGON-HF, in HFpEF [23]. The use of ACEIs/ARB in HFpEF has been previously suggested in a recent meta-analysis [24], although single large studies failed to demonstrate this relation [25, 26].

The mechanism behind the seemingly protective action of ACEIs/ARBs remains unclear, but it may have to do with the pathophysiological mechanism of HF itself. Hypertension and cardiac remodeling play a role in the pathogenesis; moreover, the renin–angiotensin–aldosterone axis is closely related to inflammation and its byproducts. This would justify the rationale behind such an effect, as well as the synergy. The benefits shown at short follow-up (Fig. 3A, B) draws attention to the shorter-acting mechanism of cardio-protection.

Beta-blockers showed a clear benefit in terms of the combined clinical endpoint, and in terms of readmission for HF, with a trend to a lower mortality. Previous studies in HFpEF patients did not show any significant effect of beta-blockers [27, 28]. However, hypotheses have been made about the mechanism of beta-blockers in HFpEF. Subendocardial ischemia is one of the mechanisms that has been suggested in the physiopathology of HFpEF. Beta-blockers may improve diastolic filling, enhancing relaxation, and decreasing subendocardial ischemia. Other mechanisms such as control of precipitant factors (hypertension, tachyarrhythmia) have been suggested for the role of beta-blockade in HFpEF.

HFpEF population is very heterogeneous; it affects elderly patients with several comorbidities (i.e. diabetes, hypertension) and different cardiac phenotypes (i.e. hypertrophic cardiomyopathy, infiltrative disease, hypertensive cardiomyopathy). Moreover, the definition of HFpEF has changed over the time, and the current European guidelines [1] define HFpEF when LVEF ≥ 50%, and HF with mid-range ejection fraction when LVEF is 40–49%. Some large studies have included a very heterogeneous profile of patients; for example, PARAGON-HF [23], included patients with LVEF ≥ 45% and any wall thickness, and failed to show any benefit from sacubitril/valsartan in comparison with valsartan. One explanation could be that the population selected presented with different entities in the spectrum of HFpEF, and the pathophysiological mechanisms and the response to therapies might have been different in each form.

In the present study, a very selected population of patients fulfilling criteria for HFpEF were included, with an LVEF ≥ 50% and with a maximal LV wall thickness of < 12 mm. In these concrete populations, the response to ACEI, ARB and beta-blockers was beneficial. The present hypothesis is that each form of HFpEF has a different profile, and a narrower approach to each entity integrating the big group of HFpEF could be useful for identifying the optimal therapy.

Interestingly, it was found that high potassium levels at entry (defined as potassium serum levels > 5 mEq/L) was a negative prognostic factor for outcome, in terms of higher readmission for HF and mortality rates. The explanation for this may be that, on the one hand, hyperpotassemia may indicate that the patient is not receiving enough non-potassium-sparing diuretics; and on the other hand, it can also reflect a certain degree of kidney failure and has been previously associated with increases in cardiovascular and HF-related events [29].

Limitations of the study

On the other hand, patients taking clopidogrel had a higher risk of being readmitted for HF, which might be explained by more coronary artery disease and vascular disease, which might increase risk for these patients.

This study has some limitations that may explain the failure to show a correlation between the presence of MGUS and clinical outcomes in HFpEF patients. In the first place, this is an observational and unicentric study, with possible selection bias that this study design implies and the limitation to extrapolate data to the general population. Second, sample size (n = 69) was not large and may have limited the ability to establish a relationship between HFpEF and MGUS. However, the findings reported herein may serve as a proof-of-concept, suggesting a need to search for MGUS in patients with HFpEF. Third, longer follow-up periods and
larger studies are needed to truly assess the impact of MGUS on survival and hospitalization for HF.

Conclusions

In conclusion, the prevalence of MGUS in HFrEF patients with no LVH was roughly 3-fold that of an age-matched general population; thus, it may be suggested that patients with MGUS be assessed for possible HF. Though a correlation was not found between MGUS and clinical outcomes for this population of HFrEF patients, longer follow-up studies are needed to fully rule out this possibility. The use of beta-blockers and ACEI or ARB reduced the combined endpoint of mortality and rehospitalization for HF in this HFrEF population, which may support the use of these treatments of these patients. Higher potassium levels may be a marker of poor prognosis in this population, and closer follow-up should be considered. Further studies are needed to clarify the state-of-the-art therapy for these patients, as their prevalence increases.

Acknowledgments

We acknowledge Oliver Shaw (Instituto de Investigación sanitaria (IIS) — Fundación Jiménez Díaz, Madrid, Spain) for his assistance in editing this article.

Funding

This work was supported by grants from Instituto de Salut Carlos III (PI19/00655), financed jointly with European Regional Development Funds (ERDF).

Conflict of interest: None declared

References

1. Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129–2200, doi: 10.1093/eurheartj/ehw128.

2. Fieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019; 40(40): 3297–3317, doi: 10.1093/eurheartj/ehz641, indexed in Pubmed: 31504452.

3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007; 93(9): 1137–1146, doi: 10.1136/hrt.2003.025270, indexed in Pubmed: 17699180.

4. Owen TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006; 355(3): 251–259, doi: 10.1056/NEJMoa052256, indexed in Pubmed: 16855265.

5. Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016; 375(19): 1868–1877, doi: 10.1056/NEJMcp15i1175, indexed in Pubmed: 27059663.

6. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012; 33(14): 1750–1757, doi: 10.1093/eurheartj/ehr254, indexed in Pubmed: 21821849.

7. Group TIMI. Criteria for the classification of mononclonal gammapathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121(5): 749–757, doi: 10.1046/j.1365-2141.2003.04355.x.

8. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2006: 3541362–9.

9. Rajkumar S, Dimopoulos M, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014; 15(12): e538–e548, doi: 10.1016/s1470-2045(14)70442-5.

10. Desport E, Bridoux F, Sirac C, et al. Centre national de référence pour l’amylose AL et les autres maladies par dépôts d’immunoglobulines monoclonales, AL amyloidosis. Orphanet J Rare Dis. 2012; 7: 54, doi: 10.1186/1750-1172-7-54, indexed in Pubmed: 22909024.

11. Sebaghat D, Zakir RM, Choe J, et al. Cardiac amyloidosis in a patient with multiple myeloma: a case report and review of literature. J Clin Ultrasound. 2009; 37(3): 179–184, doi: 10.1002/jcu.20552, indexed in Pubmed: 19177424.

12. Toor AA, Ramdane BA, Joseph J, et al. Cardiac nonamyloidotic immunoglobulin deposition disease. Mod Pathol. 2006; 19(2): 233–237, doi: 10.1038/modpathol.3800524, indexed in Pubmed: 16341150.

13. Buxbaum JN, Genega EM, Lazowski P, et al. Infiltrative nonamyloidotic monoclonal immunoglobulin light chain cardiomyopathy: an underappreciated manifestation of plasma cell dyscrasias. Cardiology. 2000; 93(4): 220–228, doi: 10.1150/000007030, indexed in Pubmed: 11025347.

14. Bossebecouf A, Allain-Maillet S, Mennesson N, et al. Pro-inflammatory state in monoclonal gammopathy of undetermined significance and in multiple myeloma is characterized by low sialylation of pathogen-specific and other monoclonal immunoglobulins. Front Immunol. 2017; 8: 1347, doi: 10.3389/fimmu.2017.01347, indexed in Pubmed: 29098000.

15. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013; 62(4): 263–271, doi: 10.1016/j.jacc.2013.02.092, indexed in Pubmed: 23684677.

16. Shah AM, Shah SJ, Anand IS, et al. TOPCAT Investigators. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail. 2014; 7(1): 104–115, doi: 10.1161/CIRCHEARTFAILURE.113.000887, indexed in Pubmed: 24249049.

17. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36(38): 2585–2594, doi: 10.1093/eurheartj/ehv338, indexed in Pubmed: 26224076.
18. Kou S, Caballero L, Dulgheru R, et al. Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. Eur Heart J Cardiovasc Imaging. 2014; 15(6): 680–690, doi: 10.1093/ehjci/jet284, indexed in PubMed: 24451180.

19. Nagueh SF, Smedset OA, Appleton CP, et al. Houston, Texas; Oslo, Norway; Phoenix, Arizona; Nashville, Tennessee; Hamilton, Ontario, Canada; Uppsala, Sweden; Ghent and Liège, Belgium; Cleveland, Ohio; Novara, Italy; Rochester, Minnesota; Bucharest, Romania; and St. Louis, Missouri. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29(4): 277–314, doi: 10.1016/j.echo.2016.01.011, indexed in PubMed: 27037982.

20. Bird J, Behrens J, Westin J, et al. Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009; 147(1): 22–42, doi: 10.1111/j.1365-2141.2009.07807.x, indexed in PubMed: 19673884.

21. Goodman HJB, Wechalekar AD, Hawkins PN. Amyloidosis, not myeloma. Br J Haematol. 2005; 128(1): 158–9; author reply 159, doi: 10.1111/j.1365-2141.2005.05441.x, indexed in PubMed: 15801970.

22. Maggioni AP, Dahlström U, Filippatos G, et al. Heart Failure Association of ESC (HFA). EURObservational research programme: the heart failure pilot survey (ESC-HF pilot). Eur J Heart Fail. 2010; 12(10): 1076–1084, doi: 10.1093/eurjhf/hfq154, indexed in PubMed: 20805094.

23. Solomon SD, McMurray JJV, Anand IS, et al. PARAGON-HF Investigators and Committees. Angiotensin-Nephrilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019; 381(17): 1609–1620, doi: 10.1056/NEJMoa1908655, indexed in PubMed: 31477594.

24. Khan MS, Fonarow GC, Khan H, et al. Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2017; 4(4): 402–408, doi: 10.1002/ehf2.12204, indexed in PubMed: 28869332.

25. Cleland JGF, Tendera M, Adamus J, et al. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27(19): 2338–2345, doi: 10.1093/eurheartj/ehl250, indexed in PubMed: 16983472.

26. McMurray JJV, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362(936): 767–771, doi: 10.1016/S0140-6736(03)14283-3, indexed in PubMed: 13678869.

27. Flather MD, Shibata MC, Coats AJS, et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26(3): 215–225, doi: 10.1093/eurheartj/ehi115, indexed in PubMed: 15642700.

28. van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al. Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2009; 53(23): 2150–2158, doi: 10.1016/j.jacc.2009.02.046.

29. Nishihara T, Tokitsu T, Sueta D, et al. Serum Potassium and Cardiovascular Events in Heart Failure With Preserved Left Ventricular Ejection Fraction Patients. Am J Hypertens. 2018; 31(10): 1098–1105, doi: 10.1093/ajh/hpy101, indexed in PubMed: 29985986.